Comparing SSRIs and Ketamine: How to Read Treatment Statistics

Important: Compounded ketamine is not FDA-approved. FDA has not evaluated its safety, effectiveness, or quality before marketing. Ketamine injection is approved for anesthesia, not psychiatric conditions. Compounded ketamine nasal spray is different from FDA-approved Spravato (esketamine), and research on other formulations or treatment settings does not establish its benefits.

A comparison chart may place an SSRI response rate beside a ketamine response rate and imply that the larger number identifies the better treatment. Without the study details, that conclusion can be misleading.

Check what the numbers measure

A response rate often means a specified improvement on a symptom scale. A remission rate uses a different threshold. A satisfaction survey asks a different question again. Before comparing percentages, find out which outcome was measured and when.

Timing matters. A score soon after treatment cannot be directly compared with a result after months of care. The proportion of people who completed the study also matters: results among completers may not describe everyone who started.

Check who received treatment

Studies may enroll people with different diagnoses, symptom severity, prior treatment experiences, and medical risks. Some use strict exclusions; others review routine clinical records. Those differences can affect the results even before considering the medication.

Keep the formulation attached to the finding

Ketamine infusion, sublingual ketamine, compounded nasal ketamine, and Spravato should not be combined into one interchangeable category. For example, the VA intravenous-ketamine study and the 2022 sublingual telehealth study investigated different routes and care arrangements. Neither is a trial of Bliss Mist Rx’s compounded nasal treatment.

A meta-analysis also depends on the quality and comparability of the studies it includes. Taking a midpoint across unrelated results does not produce a validated personal success rate or a fair head-to-head comparison.

Ask for an individualized comparison

• Which evidence applies to my diagnosis and previous treatment history?
• Was this option directly compared with the alternative we are considering?
• What are the important risks and burdens of each plan?
• What information is missing, particularly about longer-term use?

For a general overview of medication categories, see NIMH’s mental health medication resource. A clinician can help translate evidence into a decision that accounts for your priorities and circumstances.

Be cautious when a numerical comparison is used to claim that compounded ketamine is faster, safer, or more effective than approved psychiatric medications. FDA has not established those claims.

Safety and the treatment setting

Ketamine can cause sedation, dissociation, impaired thinking or coordination, nausea, increased blood pressure or heart rate, and slowed breathing. Abuse or misuse, worsening psychiatric symptoms, and urinary or bladder problems are also concerns. This is not a complete list of risks.

At home, a healthcare professional is not onsite to monitor you or respond immediately to an adverse reaction. Telehealth support does not provide the same monitoring as an onsite care team. Review these FDA ketamine risk alerts and discuss your health history, other medications, monitoring needs, and emergency plan with your clinician.

Discuss your options

Bliss Mist Rx LLC provides telehealth services; we do not manufacture or compound medication. If a clinician prescribes treatment, an independent, appropriately licensed compounding pharmacy dispenses it. A consultation does not guarantee a prescription or a particular outcome. Book a Free Virtual Appointment or Follow-Up to discuss questions about your care.

This article is general education and does not replace individualized medical advice.